ep thought year-end
set-up look decent given notabl pull-back stock recent week high
expect ep seem least top mind given bigger pictur topic play
includ polit drug price bill motion see guidanc rais
best larg cap idea insid detail
celg smid-cap amrn
host conf call et jefferi biotech team jare holz
moder key topic interest year-end contact jefferi sale
detail
oct maintain hold given number factor still need play
major ip binari overhang feb lack pipelin confid look in-
line top although ep could better given on-going cost-cut tecfidera
still qq inventori drawdown spinraza tepid
last quarter ww spinraza con
management may signal rev ep fall higher end guidanc
guidanc conserv impli flattish anyway consensu
alreadi in-lin con toward high-end
guidanc view -- key investor stock spinraza
us see weak investor read-through nv zolgensma although
still earli view aducanumab phase post-analysi complet immin
could final updat wait phase ii psp tau data remain high
risk confid progress ip settlement ipr and/or anda greater
focu swap tec pt vumer pend fda approv immin
oct continu like stori enbrel ip risk mostli move
behind pipelin drug come also see upsid
consensu otezla deal accret look mix bag
in-lin revenu ep possibl better guidanc tweak toward
higher end slightli rais view although consensu top-end alreadi
rais ep consensu neulasta
biosimilar look anyth beyond alreadi expect modest share gain
wild-card enbrel management emphas net price could actual flat
year better prior year price declin cours bigger pictur
stock whether kra sentiment get bullish/bearish
competitor put data end octob close otezla deal ye
w/ upsid ep competitor wont matter view take time
bcma updat gen gen earli go/no-go pivot
studi big phase tezepelumab asthma data expect patient
 see pullback smid-cap might get interest
continu page detail analys other insid
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
summari chang
pleas see import disclosur inform page report
oct look in-lin better ep look least in-lin better given
continu strong growth biktarvi stabil hcv script on-going expens
manag possibl rais guidanc least narrow high end
prior guidanc conserv view recent got approv descovi
prep use last week notabl focu switch next
quarter given around truvada goe gener fall insight eu launch
biktarvi also sourc upsid previous less adept hiv share
eu particularli strong profil suggest compet
better eu inde bigger pictur see issu focu investor
stock year-end particularli around actual
catalyst stock day much prep truvada swap management think
achiev descovi next quarter search cfo head remain
outstand hope get done much bd get
done w/o head cfo nash strategi look like
phase ii atla combo data look particularli strong
oct estimate see good predict guidanc rais like
stock head big cf tripl launch multipl pipelin readout note
cf revenu estim consensu ep
consensu believ good chanc rais full-year
revenu guidanc consensu model total cf revenu vs
jefferi alreadi guidanc
annual revenu impli sale alreadi
lower-end guidanc addit assum flattish sale growth
vs would suggest sale
would alreadi high-end guidanc stock includ progress
england franc reimburs possibl england new
cf pill tripl year think expect phase ii
data possibl confid around level endpoint fda
workshop recent much readthrough import place upcom
phase crsp gene edit data management reiter report least
coupl patient year-end
celg oct estimate celg day part relat cvr
go report phase ii pivot data dlbcl show data
competit kite/gild yescarta cr durabl final
file bla sinc matter cvr file ye
plenti time meet cvr deadlin approv full
detail bcma pivot studi readout consensu assum least
top-lin press releas full data present may
file occur ad month approv would give
time approv cvr deadlin ozanimod pdufa date
march plenti time meet cvr deadlin even
anoth modest delay although street would want see delay
oct estimate focu call launch dynam recent approv
ultomiri soliri follow-on product /eu approv dec pnh
expect soliri launch nmosd approv patent strategi
soliri us eu updat guidanc previous note ultomiri
price discount soliri pnh/ahu pdufa ultomiri
pleas see import disclosur inform page report
ahu patient convers conveni ultomiri soliri rapid
could potenti impact sale growth note soliri account
total revenu histor provid conserv guidanc initi
up expect increment cours year total
revenu estim in-lin vs consensu total revenu vs con
ep vs con
amrn oct estimate note script qtd time high track
sale inde possibl total sale could actual fall littl higher
toward rang due slightli inventori build -- higher
consensu around manag note juli mani
increment order increas purchas vascepa inventori anticip
receiv provid compani ad cushion event
vascepa revenu trajectori acceler faster expect inde script
qtd also note increas salesforc octob anoth
potenti posit driver acceler sale even debat
whether increas salesforc demand great
sens demand deceler need spend get
think quarter big compon stock thesi assum sale good
think adcom right around corner continu
believ perhap probabl someth goe astray and/or fda
anoth delay approv think probabl get approv
time pdufa fda want discuss drug popul
uniqu mechan drug support cvot result
oct estimate focu call potenti price strategi valrox
gene therapi hemophilia eu regulatori submiss potenti
comment launch prepar valrox enrol updat
valrox commerci launch progress palynziq fda approv june
reiter cours year estim line vs
consensu total revenu vs con lp vs con
buy pt recent initi coverag three key differenti
these korlym patent like key patent whole anda litig
conserv assum ptab may institut patent
good chanc stay valid effect prevent gener entri mid/lat
relacoril suffici differenti korlym efficaci safeti replac
korlym expand market share time gener mifepriston
approv could cannib korlym share relacoril appear neg
impact base cush syndrom doc survey print expect korlym
continu robust growth vs given price increas
august continu strong demand new exist pt reach high end
sale guidanc full w/ yoy growth
vs move forward ptab decis whether institut
key valu inflect point co expect see move non-
institution/institut decis w/ skew probabl posit outcom non-
institut addit complet enrol relacoril studi
pleas see import disclosur inform page report
may creat /- volatil howev hold strong convict relacoril
ultim gener differenti data vs koylym base moa result
hold pt imvexxi co recent receiv coverag cumul
commerci coverag live co await decis aetna commerci
four part plan expect see continu strong total script
refil expand coverag robust demand sale could catch
make sale reach co guidanc howev note gton
remain key metric watch expect see
slow net revenue ramp outer year due uncertain adjud rate rebate/
discount/co-pay assist cap peak gton recent addit
coverag co sign commerci pharmaci live bijuva see
quicker progress win payer coverag bijuva vs imvexxi expect de
minimi sale commerci live quicker insur coverag
view bijuva could faster higher gton margin expans three top
plan commerci live recent start adjud annovera co claim
unrestrict coverag commerci plan state w/o state w/ co-pay
regardless mandat howev note decis annovera
new contracept categori remain key unleash full market potenti
effect compet nuvar potenti gx expect meaning revenue
annovera co soft launch sept plan nation launch
buy pt on-going lawsuit fda tradipit continu
key overhang share howev base co develop strategi
see timelin risk gastroparesi atop dermat due larg size pivot
nt need safeti studi motion sick episod vs chronic condit
scenario analysi suggest long court decis posit neg
come co abl time complet lt safeti studi meet
current assumpt approval/launch recent respons fda
seal come co expect court could make final decis
month current base case co need conduct anim tox studi
time resolut delay develop plan expect
meaning updat proceed earn given seal natur fda
respons expect two commerci product world-wide hetlioz
sale yoy growth us fanapt sale yoy growth
expect stronger-than-expect perform and/or potenti guidanc rais well
receiv street clinic pipelin program look updat
enrol statu tradipit gastroparesi studi tradipit ad/cp studi
progress plan hetlioz jld follow potenti pre-nda meet
outcom hetlioz sm
estimate focu call potenti impact gener remodulin
sale launch updat line extens product includ implant system
remodulin isr remun sc remodulin pump system launch updat
orenitram combin therapi pdufa data timelin ralinepag
potenti updat guidanc previous note price decreas
remodulin sandoz gener avail price discount
exclus sandoz gener exclus expir addit gener entri immin
creat price pressur remodulin impact sale growth
pleas see import disclosur inform page report
total revenu estim in-lin vs consensu total revenu
vs con lp vs con
complet detail full analysi compani insid report
pleas see import disclosur inform page report
tabl content
pleas see import disclosur inform page report
inbrija sale estim consensu recent
announc signific formulari win past two month script still track
low indic sale could miss consensu stage launch
lower pt due launch under-perform expect sale
came lower expect script also track lower previous
expect reiter hold rate
pictur share declin report low inbrija sale
stock continu trade within rang market cap
expect continu pressur inbrija could miss consensu sale
slow launch key issu stock overhang compound debt
due may need refin higher rate believ stock
continu trade range-bound issu fulli resolv
script appear softer-than-expect inbrija launch start weak report
revenu script per im launch continu soft sale
track grow q/q gener sale base script
consensu thu think sale could miss lower
estim
secur reimburs key launch nice see increas
cover live last two month commerci
medicar seem make much impact
pleas see import disclosur inform page report
pleas see import disclosur inform page report
fiscal year end figur mm except per us selincro/fampyra ex-u royalti zanaflex author gener qutenza capsaicin inbrija/civita us eu sale inbrija us sale inbrija eu sale licens total sale marketing- a- asset asset acquisit relat chang fair valu acquir conting total incom oper pre-tax provis incom tax net ep outstand share outstand equiti research
thought
ep estim rel in-lin consensu
vascepa revenu estim roughli consensu higher revenu
estim support im data script growth q/q suggest sale
exclud inventori although surpris
revenu came rang given compani hint could
inventori build
ep estim ahead consensu driven slightli
lower opex estim full-year vascepa revenu estim in-lin
consensu toward upper end guidanc see lower
guidanc rang conserv sinc vascepa sale would need gener
quarter slightli reach
could see amrn manag tighten vascepa guidanc rang
compani plan increas salesforc rep octob
plan submit dtc ad oct ahead spring launch estim
dtc ad cost also agre amrn invest heavili make vascepa
big possibl bear argu plan increas consensu opex
street expect happen soon howev debat capit
requir big deal patient demand vascepa sale turn
sg expens manag like hire fulli train addit
sale rep july-sep estim annual sg expens could increas
assum sale rep salari apiec would translat
increas sg cost sg expens estim
vs con factor sale rep salari anoth
dtc ad believ amrn may start incur dtc expens earli model
addit cost
script continu reach record high
note script qtd track sale though total sale
could fall toward rang due inventori build manag note juli
mani increment order increas purchas vascepa inventori
anticip receiv provid compani ad cushion
event vascepa revenu trajectori acceler faster expect inde
script qtd assum slightli lower vs estim
off-set slightli higher captur rate vs estim
pleas see import disclosur inform page report
pleas see import disclosur inform page report
pleas see import disclosur inform page report
sep amrn toplin reduce-it datanov amrn present reduce-it data ahamar present addit reduce-it data script projectionsvascepa trxvascepa nrx exhibit amrn incom statement
pleas see import disclosur inform page report
fiscal year end figur mm except per incom statementproduct international- licens vascepa eu royalties- total product oper research develop sale gener administr total oper incom total loss chang fair valu deriv liabilities- extinguish debt- interest interest incom net- incom pre-tax provis tax tax prefer stock net incom attribut common ep basic dilut basic dilut outstand share outstand dilut share outstand fulli dilut w/ option equiti research
expect manag tighten rais full-year revenue/ ep guidanc
revenu could tighten rang vs con
rais ep could tighten rang
vs con rais
revis ep estim consensu
rais ep primarili due lower opex assumpt current in-lin
consensu rais revenu estim vs con
higher enbrel sale assumpt overal think top-lin result gener
middl in-lin largest variabl come sensipar follow
enbrel neulasta revenu estim shi consensu driven
mostli lower sensipar sale estim vs con even though
neulasta sale also variabl due on-going biosimilar competit consensu
model usa sale declin roughli y/i trajectori
gener corrobor im data biosimilar taken around market
share june-end
ww revenu estim in-lin consensu toward
high-end guidanc lower sensipar estim vs con
off-set slightli higher estim enbrel vs con
neulasta vs con feel comfort durabl
franchis ep estim consensu guidanc
driven primarili lower share count estim vs con
assumpt factor current guidanc
repatha sale steadili grow q/q due improv access model sale
in-lin con vs con
aranesp sale declin faster rate due long-act short-act
competit assum y/i declin vs con y/i
addit biosimilar launch kanjinti herceptin biosimilar
approv june sku version pdufa date oct also
mvasi avastin biosimilar launch juli
sensipar sale uncertain due on-going legal proceed gener
recent note inventori gener sensipar still remain market
revenu reflect non-recur natur
mileston payment receiv assum revenu in-lin
con
oper margin expect lower due time expens assum
margin vs
opex flat y/i absolut basi model flattish y/i growth
cog flat slightli depend volum estim flattish y/i growth in-
line consensu
 expens increas single-digit percentag pipelin advanc
model y/i growth in-lin consensu
sg declin launch expens normal continu resourc
alloc disciplin estim y/i declin in-lin con
pleas see import disclosur inform page report
repurchas activ around estim share repurchas
slightli higher consensu
otezla deal seem accret especi make look even better
otezla probabl around add
revenu estim ebit margin ep accret
benefici boost outlook revenu
ep compound-annual-growth-rate rev ep first year mostli
integr minim opex benefit guid obviou synergi time given
exist enbrel salesforc ou great synergi humira biosimilar
salesforc stand-alon grow infrastructur japan well
assum deal close
sg increas y/i driven cost associ on-going
support otezla lesser extent cost insur effect transit
 overal increas y/i support increas otezla intern
tax rate see increas
share repurchas look similar pace
oper repurchas share total
neulasta biosimilar taken market share past year
fulphila udenyca two biosimilar approv although
surpris see other enter market accord im data
aug fulphila garner market share month launch
m/m udenyca taken share eight month launch
m/m aug sale fulphila m/m
udenyca m/m compar neulasta flattish m/m
repres combin biosimilar/brand neulasta sale
notabl onpro sale aug total brand neulasta
im suggest sale may partial block
estim take combin share y/i
gener in-lin consensu forecast neulasta sale
august im data suggest fulphila taken share total neulasta market
juli
estim taken pre-fil syring market
sep su assert fulphila infring two patent case
on-going trial date schedul yet
launch udenyca earli januari taken impress market
management believ udenyca take total unit share
pleas see import disclosur inform page report
estim take pre-fil syring market
howev note market share gain realiz onpro
pre-fil syring format segment market oncolog clinic
hospit
fact approv udenyca transit pass-through payment statu
hospit effect april grant udenyca month transit pass-
statu mean udenyca calcul list price wac
juli establish asp repres list price
septemb note make good progress onpro
devic compani disclos devic detail competit reason
udenyca sale includ
exhibit neulasta vs udenyca/fulphila sale time base monthli im sale
pleas see import disclosur inform page report
underli patient demand cgrp migrain drug look solid
aimovig trx track around q/q believ could translat usa sale
vs con depend amount free sampl provid
patient quarter amount reduct q/q amount paid
prescript think
percentag increas modestli quarter go forward free drug sampl
convert dollars/revenu
estim usa aimovig sale consensu
consensu usa estim base sampl
rate q/q
importantli teva ajovi lli emgal taken combin script
teva report ajovi sale q/q report
emgal sale
teva anticip us ajovi sale fall slightli shi
total cgrp market track run-rat
note bla aldr eptinezumab fourth cgrp competitor pdufa date
feb expect launch eptinezumab presum administ
via infus clinic differ reimburs dynam at-hom
inject current market feedback share given profit incent tri
give iv infus pt
prescript share declin start trx/nrx
stabil teva
script declin grow grow cgrp market track
pleas see import disclosur inform page report
 aimovig aimovig quarterli refil weekli captur predict rev build quarterli sale exhibit aimovig script project migrain
pleas see import disclosur inform page report
aimovig nrx ajovi ajovi nrx emgal emgal nrx script track usa
exhibit repatha vs regn/sni praluent script project left red line repres histor im data
pleas see import disclosur inform page report
pleas see import disclosur inform page report
sale trend parsabiv sensiparparsabivsensipar exhibit neulasta onpro monthli sale time
pleas see import disclosur inform page report
share sale neulasta onproneulasta pre-fil neulasta onpro share exhibit monthli sale comparison versu zarxio granix
pleas see import disclosur inform page report
exhibit guidanc versu consensu jefferi estim
pleas see import disclosur inform page report
jefco varianceguidanceconsensu jefco variancetot product sale t-vec ivabradin even total total cog sg oper tax net fulli dilut non-gaap exhibit incom statement
pleas see import disclosur inform page report
fiscal year end figur mm except per incom statementproduct repatha parsabiv- erenumab cgrp biosimilars- even romo otezla kra tezepelumab asthma bcma oncology/bit mn pharma total sale research sell gener total oper interest interest incom incom provis incom net non-gaap ep ep outstand outstand equiti research
think manag could signal full-year revenu probabl fall toward
higher-end guidanc vs con jefferi estim
ep similarli trend closer high-end vs con new
jefferi estim think ep turn higher-end due
part recent discontinu aducaunumab phase elenbecestat program
alzheim partner eisai phase ii program ipf well
less-than-expect bd activ quarter
rais ep estim reduc expens
lower consensu still higher q/q y/
origin anticip busi develop bd activ pick consider
start follow discontinu aducanumab program
notabl bd announc nightstar acquisit transact offici close
june believ expens recogn incom statement
anyway reduc forecast fall closer
histor norm still assum increas activ q/q y/i
meanwhil revenu estim in-lin consensu think
bigger swing factor quarter spinraza came light ou
geographi notabl spinraza revenu decreas q/q ou difficult
comp driven one-tim posit price benefit franc time shipment
transit mainten dose ww spinraza estim con
sale
new ep estim increas in-lin con
toward high-end guidanc even though rais ep estim
expens reduct anticip bd activ instead pick
also ww revenu estim in-lin consensu fall toward
midpoint guidanc
note three competit develop track
juli fda approv rituxan biosimilar ruxienc nhl cll gpa
mpa ra grant set launch date caution
rixutan revenu impact biosimilar settl roch
march key patent also even though celltrion/teva truxima
approv late biosimilar similarli launch yet approv
cancer indic due patent challeng profit share rituxan/gazyva
total suggest franchis
sep uspto institut accept review anoth tecfidera ipr file
sawai japens gener compani sawai assum ipr timelin final
court decis compani probabl set occur sometim feb think
sawai institut add complex pressur stock sinc chanc
settlement uncertain given like settl gener ipr
filer count around anda filer still outstand trial decis perhap later
would wood even resolv ipr situat
separ note potenti tecfidera product aim launch late
pleas see import disclosur inform page report
banner life bafiertam tecfidera gener revenu
track reach
expect zolgensma initi adopt center around newborn year
note eu/japan approv push back oral risdiplam nda file
remain track expect drug receiv broad label type
spinraza gener sale track reach
ms channel drawdown compar
sale benefit lower expect continu
discontinu rate current mid-singl digit annual
ex-u revenu impact continu transit mainten dose
expect slight declin rituxan revenu due launch biosimilar
complet chang tax profil result decreas bp
non-gaap tax rate benefit expect recur
benefit opex reduct relat aducanumab
discontinu net
current revenu guidanc rang driven primarili uncertainti
thought tecfidera sale
tecfidera script q/q impli script revenu usa assum
inventori chang vs consensu note gener lower
expect continu estim return rang
tecfidera inventori trend follow
inventori saw draw q/q
inventori level rel constant q/q build drawdown
inventori level drawdown
inventori level rel constant q/q
inventori level increas q/q
inventori level decreas q/q
inventori level decreas q/q
inventori level stabl q/q
inventori level increas q/q
inventori level decreas q/q
inventori level decreas q/q
assum inventori level remain unchang
pleas see import disclosur inform page report
vumer nda accept feb fda decis slate
plan launch drug ahead tecfidera ipr outcom earli vumer
confer better gi safeti profil tecfidera recent confer
ceo michel vounatso note compani strategi switch patient
tecfidera vumer instead expand overal ms market clear vumer
advantag lie dose acut earli phase patient treatment
may experi flush gi side effect major incent switch
patient alreadi stabl repres vast major
ocrevu multipl sclerosi market
ocrevu im script unreli monitor whether tecfidera script
affect launch ocrevu gener ww sale
mostli us sale repres fastest launch roch histori
emphas ocrevu impact tecfidera tysabri significantli least
alreadi expect notabl posit
nv plan submit snda ofatumumab drug show
high efficaci data rm patient
nv mayzent siponimod approv march rrm spm ci
drug appear minim affect tecifdera tysabri revenu thu far
pleas see import disclosur inform page report
predict predict predict predict year end figur mm except per chf us- ous- ocrevu usd us- ous- royalti total royalti us- ous- report consensu comparison tabl
exhibit guidanc versu consensu jefferi estim
pleas see import disclosur inform page report
jefco varianceguidanceconsensu jefco variancetot revenu us us us us cog sg oper tax net fulli dilut factset estim non-gaap exhibit incom statement
pleas see import disclosur inform page report
fiscal year end figur mm except per total rituxan vumer fampyra oral fumar biosimilar rituxan ocrevu royalti broken total good total research sale gener oper incom incom pre-tax provis equiti loss investe net tax- net net incom adjust dilut ep ep basic dilut outstand share outstand equiti research
thought
ep result straightforward expect see surpris
ep estim in-lin consensu estim
ahead consensu due slightli higher revlimid estim off-set
slightli lower expens expens estim translat oper margin
assumpt in-lin con guidanc could see
celg reiter net product sale guidanc vs con rais ep
guidanc vs con
im data show otezla script grow q/q suggest usa sale
probabl slightli consensu even though low single-digit
percentag q/q growth compar q/q surpris rel
quarterli script growth flat q/q model build conservat
even though celg saw channel build
believ return histor norm vs assum
would impli usa sale would impli sale
sale ww us/ ex-u consensu
believ help inventori build decreas quarter
forecast world-wide otezla revenu vs guidanc
slightli consensu
believ im track usa revenu would mean
ex-u revenu would surpass year reach manag
guidanc rang
believ ex-u otezla sale achiev sale
suggest annual run rate alreadi
model us sale ex-u sale
pleas see import disclosur inform page report
exhibit otezla sale project base im script
pleas see import disclosur inform page report
app estimatesquarterli refil weekli captur predict revenu build quarterli sale otezla nrx exhibit expect approv date product tradeabl cvr
pleas see import disclosur inform page report
expect news flowtimingnotesozanimodfda accept reviewjun fda accept fda approvalch standard reviewapprov deadlin cvrdec liso-cel report pivot data r/r dlbcl transcend dec bmi guidanc esmo fda submiss base guidanc esmo potenti fda approvalbi prioriti reviewapprov deadlin cvrdec ide-cel report pivot data r/r mm karmma dec estimate guidanc note submiss base guidanc fda guidanc deadlin cvr calculationcvr calc upon fda approv three productsd structur product approv dec dec stock celg holder cvr payment celg holder cvr payment celg stock celg time deal expect close earli celg consensu comparison tabl
exhibit guidanc versu consensu jefferi estim
pleas see import disclosur inform page report
jefco varianceguid consensu jefco us us us us net product total cog sg oper tax net fulli dilut celg non-gaap exhibit celg incom statement
pleas see import disclosur inform page report
fiscal year end figur mm except per incom statementtot product idhifa- royalti pipelin revenue- fedratinib- ozanimod- luspatercept- marizomib- total total oper research develop sale gener administr oper incom total interest invest incom interest incom expens pre-tax provis net ep basic dilut outstand share outstand equiti research
rais ep estim con mostli due
higher hcv revenu script q/q lesser opex estim sg
increas share repurchas assumpt opex estim slightli
consensu revis share repurchas assumpt share
still consensu roughli share total product sale estim
in-lin consensu includ individu product estim
previous reduc sg expens despit recent selonsertib
program discontinu believ would increas spend
includ prior filgotinib launch later
specif recent fda discuss suggest could file nda earli
howev awar nda file quarter think sg
begin pick closer
revis ep estim consensu
wherea revis revenu estim consensu decreas
sale estim due lesser biktarvi sale assumpt base im
script trend off-set slightli higher hcv estim howev slightli lower
revenu off-set reduc opex assumpt full-year estim
sg in-lin con toward midpoint
guidanc believ could tighten product sale guidanc
vs con jefferi driven continu hiv
growth increas hcv visibl
hcv script q/q
us hcv script q/q compar sale gener
stabl usa script appear stabl im model suggest
script could track usa sale would suggest
sale growth quarter vs declin consensu assum
y/i declin hcv sale help eu clawback benefit
sale fall favor toward lower-end manag origin
guidanc case revenu growth hiv franchis
off-set neg market dynam hcv franchis view
hcv sale includ us ou
estim ww sale q/q in-lin consensu
back eu clawback would suggest q/q declin
us forecast sale moder q/q growth
estim hcv sale ww y/i declin in-lin consensu
y/i better guidanc
hcv data point thought
mavyret sale exceed vs
respect hold global hcv market share
expect global hcv sale reach vs previous equal
split ex-u
pleas see import disclosur inform page report
impli us sale compar signal continu
market stabil exit roughli market share
manag previous said expect hcv revenu fall
could prove conserv
exhibit harvoni sovaldi epclusa vosevi script project
pleas see import disclosur inform page report
harvoni quarterli refil weekli treatment captur predict rev sale build/account quarterli sale quarterli refil weekli treatment captur predict rev sale build/account sof-vel quarterli sale total us hcv sale us hcv rev exhibit ensu estim annual hcv sale world-wide
pleas see import disclosur inform page report
pleas see import disclosur inform page report
biktarvi script continu grow week sinc feb launch think
consensu ww estim q/q growth achiev vs
ww weekli trx growth continu trend upward suggest biktarvyi
track reach consensu estim script
q/q vs suggest usa sale inventori
build assumpt vs jefco
descovi approv track amount patient swap
amount patient swap truvada descovi remain open question
truvada go gener sometim fall investor close monitor
script determin whether patient switch descovi approv octob
note script truvada descovi remain flattish last month
although im script could partial block
exhibit compar launch trajectori biktarvi vs hiv drug launch
pleas see import disclosur inform page report
biktarvi quarterli refil weekli captur predict rev build/account quarterli sale jefco quarterli estimateestim refil ratenrx weekli growthtreat monthli script volumesweektim seri analysi -weekli es recent hiv drug launchesbiktarvi descovi odefsey genvoya juluca dovato exhibit gsk vs im script time
pleas see import disclosur inform page report
exhibit guidanc versu consensu jefferi estim
pleas see import disclosur inform page report
jefco varianceguid consensu jefco varianceproduct hcv non-hcv product total total cog gross sg oper tax net fulli dilut factset/ bloomberg estim impli non-gaap exhibit incom statement
pleas see import disclosur inform page report
fiscal year end figur mm except per incom statementhcv harvoni epclusa sof vosevi hiv atripla truvada complera stribild viread genvoya descovi odefsey biktarvi bictegravir/f/taf hiv viread gener product axi-cel zydelig ambisom vemlidy- viread tdf exclud product sale antivir franchis royalti contract total oper research develop sale gener administr total oper incom oper total pre-tax provis effect tax rate loss attribut non-controlling net incom ep basic dilut outstand basic share outstand dilut equiti research
thought
ep estim consensu estim driven
higher opex revenu quarter roughli line consensu
estim us/eu revenu estim oca line
consensu note management highlight sale would impact typic summer
season model expens sg slightli
consensu respect
note intercept increas wac price oca august
last price increas occur juli intercept go
ep estim consensu estim us/
eu revenu estim oca slightli consensu
ww full year sale oca management net sale guidanc rang
estim expens consensu
estim convers model sg expens line
consensu estim
script qtd track howev sale could come
lower depend much inventori build util call
management note us sale benefit specialti pharmaci order outpac prescript
trend suggest would normal go forward estim inventori build
depend drawdown sale could come low
around
pleas see import disclosur inform page report
pleas see import disclosur inform page report
sep dear dr letter publishedsep fda safeti commun feb updat ocaliva labelfeb phase result actualnrx actual exhibit incom statement
pleas see import disclosur inform page report
million except per year end licens ocaliva pbc us ous- ocaliva nash us ous- total cost expens cogs- research sale gener total oper cost incom loss total incom taxes- net incom net loss per share loss per share equiti research
total cf revenu estim consensu due higher
orkambi kalydeco sale estim ep estim consensu
consensu model q/q sale declin kalydeco
orkambi wherea model increment q/q growth cf line-item think
quarterli sale continu grow given sale grew organ
q/q driven younger patient start orkambi/kalydeco eu patient start
symdeko symdeko estim rel in-lin consensu
note saw inventori drawdown experienc build-up
believ good chanc rais full-year revenu guidanc
consensu model total cf revenu vs jefferi
alreadi guidanc annual
total revenu includ inventori drawdown impli sale
alreadi lower-end guidanc addit assum flattish sale
growth vs would suggest
sale would alreadi high-end guidanc
expect see revenu growth deriv symdeko ex-u geographi
addit label expans driver includ symdeko launch eu patient age
 germani symdeko continu penetr us patient age
orkambi launch canada eu patient age repres new market
exhibit guidanc versu consensu jefferi estim
believ abl deriv y/i revenu growth addit
ex-u sale orkambi symdeko drug garner market share
canada australia european region and/or launch addit countri
instanc orkambi approv dec children age canada
eu well kalydeco jan children age canada also
note franc uk would definit repres upsid surpris sinc consensu
exclud revenu two countri symdeko sale growth due new
entri age popul approv june plu continu penetr
orkambi-experienc patient meanwhil us revenu okambi kalydeco
remain flat-to-down y/i off-set symdeko us sale growth
pleas see import disclosur inform page report
guidanc vs consensu vs jefferi estimate prior estimate total cf mean factset figur exhibit project cf revenu product
pleas see import disclosur inform page report
pleas see import disclosur inform page report
fiscal year end figur mm except per incom kalydeco kalydeco orkambi orkambi symdeko- symdeko us- symkevi row- tripl pill- tripl pill us- tripl pill row- gsk royalti revenu collabor total revenu revenu total non- product revenu royalti research sale gener total oper incom income/ expens incom loss provis incom net incom loss ep basic dilut non- share alexion
factset visibl alpha jefferi
focu call launch dynam recent approv ultomiri soliri
follow-on product /eu approv dec pnh expect
soliri launch nmosd approv patent strategi soliri us
eu updat guidanc previous note ultomiri price
discount soliri pnh/ahu pdufa ultomiri ahu
patient convers conveni ultomiri soliri rapid could
potenti impact sale growth note soliri account
alxn total revenu
histor provid conserv guidanc initi up expect
increment cours year
total revenu estim in-lin vs consensu total revenu
vs con ep vs con
pleas see import disclosur inform page report
factset jefferi
focu call potenti price strategi valrox gene therapi
hemophilia eu regulatori submiss potenti comment
launch prepar valrox enrol updat valrox
commerci launch progress palynziq fda approv june potenti
histor provid well-project guidanc reiter cours
year
estim line vs consensu total revenu vs con
 lp vs con
pleas see import disclosur inform page report
focu call potenti impact gener remodulin sale
launch updat line extens product includ implant system remodulin
isr remun sc remodulin pump system launch updat orenitram
combin therapi pdufa data timelin ralinepag
previous note price decreas remodulin sandoz gener
avail price discount exclus sandoz gener
exclus expir addit gener entri imin creat price pressur
remodulin impact sale growth
total revenu estim in-lin vs consensu total revenu
vs con lp vs con
visibl alpha jefferi
pleas see import disclosur inform page report
